Abstract
The article is devoted to the analysis of clinical and anthropometric indicators of 38 children and adolescents with pituitary dwarfism in the Stavropol region, receiving replacement therapy with recombinant growth hormone (rGH). The authors demonstrated a high growth stimulating efficacy of the rGR, as well as a positive impact on the level of blood cholesterol in children with somatotropic deficiency. Prognostic factors influencing the effectiveness of treatment were found (chronological age of initiation of therapy, baseline SDS of growth). In particular, it is shown that therapy with preparations of GH in children aged 8 to 10 years allows you to achieve a higher growth-stimulating effect in comparison with patients whose treatment is carried out at a later age. The study of the relationship between the initial deviation of the length of the body and the results of therapy in patients with growth hormone deficiency illustrates that a pronounced lag in growth is a predictive factor provides a more significant effect drugs rGR.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
